N-terminal pro B-type natriuretic peptide (NT-proBNP) has demonstrated diagnostic and prognostic value in heart failure (HF). Clinical guidelines, including those of the National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand, recommend measuring NT-proBNP in patients with suspected acute or chronic HF, when the diagnosis is uncertain, in order to expedite either early diagnosis or early exclusion of HF. Very high NT-proBNP concentration carries a poor prognosis and changes in NT-proBNP correlate with clinical course, facilitating individualised clinical management.
This educational activity was developed by MdBriefCase, with funding from Roche Diagnostics.